Revolutionizing Dermatological Treatment: The MIRARI Cold Plasma System’s Synergistic Approach to Phototherapy

May 5, 2024

Back
Featured image for “Revolutionizing Dermatological Treatment: The MIRARI Cold Plasma System’s Synergistic Approach to Phototherapy”

Introduction

In the ever-evolving landscape of dermatological treatments, the quest for innovative and effective therapies is always at the forefront. Among the most promising developments in recent years is the emergence of the MIRARI Cold Plasma System, a cutting-edge device that is harnessing the synergistic potential of cold atmospheric plasma and phototherapy to revolutionize the way we approach skin conditions.

As a healthcare professional, staying informed about the latest advancements in dermatological treatments is crucial for providing the best possible care to your patients. In this comprehensive article, we will dive deep into the world of cold atmospheric plasma (CAP) and phototherapy, exploring how the MIRARI Cold Plasma System is leveraging the unique properties of these two modalities to offer a transformative approach to treating a wide range of skin disorders.

By the end of this piece, you will have a thorough understanding of the scientific principles behind CAP and phototherapy, the current landscape of dermatological applications, and the immense potential of the MIRARI system to enhance therapeutic outcomes. Armed with this knowledge, you will be well-equipped to make informed decisions about incorporating this innovative technology into your practice, ultimately improving the lives of your patients.

So, let’s embark on this journey together and discover how the MIRARI Cold Plasma System is harnessing the synergistic potential of cold atmospheric plasma and phototherapy to shape the future of dermatological treatment.

Understanding Cold Atmospheric Plasma (CAP) and Its Therapeutic Potential

Before we delve into the specifics of the MIRARI Cold Plasma System, it’s essential to establish a solid understanding of cold atmospheric plasma (CAP) and its unique properties that make it a promising tool in dermatological therapy.

What is Cold Atmospheric Plasma (CAP)?

Plasma, often referred to as the fourth state of matter, is an ionized gas consisting of electrons, ions, and neutral particles. While natural plasmas, such as lightning and the sun’s corona, exist at extremely high temperatures, cold atmospheric plasma (CAP) is a unique form of plasma that is generated at or near room temperature and atmospheric pressure.

CAP is created by applying a high voltage electrical field to a gas, such as air or helium, which leads to the formation of a plasma discharge containing various reactive speciesUV radiation, and other biologically active components.

The key characteristics of CAP that make it attractive for medical applications include:

  1. Low temperature: CAP remains close to room temperature, allowing for safe application to biological tissues without causing thermal damage.
  2. Versatility: By adjusting parameters such as gas composition, voltage, and frequency, the properties of CAP can be fine-tuned for specific therapeutic effects.
  3. Multiple modes of action: CAP contains a complex mixture of reactive oxygen and nitrogen species (RONS), UV radiation, and electromagnetic fields, which can work synergistically to modulate biological processes.

Therapeutic Mechanisms of CAP

The therapeutic potential of CAP stems from its ability to interact with biological systems through various mechanisms, including:

  1. Antimicrobial effects: The reactive species generated by CAP, such as ozone, hydrogen peroxide, and nitric oxide, have potent antimicrobial properties. These species can disrupt bacterial cell membranes, damage DNA, and inhibit essential metabolic processes, making CAP an effective tool for treating skin infections and promoting wound healing.
  2. Immunomodulation: CAP has been shown to modulate immune responses in the skin by influencing the production of cytokines, growth factors, and other signaling molecules. This immunomodulatory effect can help to reduce inflammation, promote tissue repair, and regulate aberrant immune responses in conditions such as psoriasis and atopic dermatitis.
  3. Stimulation of cell proliferation and differentiation: CAP has been demonstrated to stimulate the proliferation and differentiation of various skin cells, including keratinocytes, fibroblasts, and endothelial cells. This property can be harnessed to promote wound healing, skin regeneration, and the treatment of age-related skin changes.
  4. Induction of apoptosis in malignant cells: Some studies have suggested that CAP can selectively induce apoptosis in malignant cells while sparing healthy cells, making it a potential tool for the treatment of skin cancers.

As research continues to unravel the complex biological interactions of CAP, it is becoming increasingly clear that this unique form of plasma holds immense potential for transforming the landscape of dermatological therapy. In the following sections, we will explore how the MIRARI Cold Plasma System is leveraging the power of CAP in combination with phototherapy to offer a revolutionary approach to treating skin conditions.

Phototherapy: A Cornerstone of Dermatological Treatment

Phototherapy, the use of light to treat various skin conditions, has been a mainstay in dermatology for decades. In this section, we will discuss the fundamentals of phototherapy, its mechanisms of action, and its current applications in dermatological practice.

Principles of Phototherapy

Phototherapy involves the controlled exposure of the skin to specific wavelengths of light, most commonly in the ultraviolet (UV) spectrum. The two main types of UV light used in phototherapy are:

  1. UVA (320-400 nm): UVA has longer wavelengths and can penetrate deeper into the skin. It is often used in combination with photosensitizing agents, such as psoralen, in a treatment known as PUVA (psoralen plus UVA) therapy.
  2. UVB (280-320 nm): UVB has shorter wavelengths and is primarily absorbed in the epidermis. Narrowband UVB (NB-UVB), which emits light at a specific wavelength around 311 nm, is the most common form of UVB phototherapy.

The therapeutic effects of phototherapy are mediated through various biological mechanisms, including:

  1. Immunomodulation: UV light can suppress the activity of T cells and other immune cells in the skin, helping to reduce inflammation and regulate aberrant immune responses in conditions such as psoriasis and atopic dermatitis.
  2. Regulation of cell proliferation and differentiation: Phototherapy can help to normalize the excessive growth and abnormal differentiation of skin cells, which is a hallmark of conditions like psoriasis.
  3. Induction of apoptosis: UV light can cause DNA damage and induce apoptosis in hyperproliferative and malignant skin cells, making it a useful tool for treating conditions such as cutaneous T-cell lymphoma and precancerous lesions.

Clinical Applications of Phototherapy

Phototherapy is widely used in dermatology for the treatment of a variety of skin conditions, including:

  1. Psoriasis: Both PUVA and NB-UVB have been shown to be highly effective in the treatment of moderate to severe psoriasis, leading to significant improvements in symptoms and quality of life.
  2. Atopic dermatitis: NB-UVB is a valuable treatment option for patients with atopic dermatitis, particularly those who have not responded adequately to topical therapies.
  3. Vitiligo: NB-UVB is considered a first-line treatment for vitiligo, as it can stimulate the production of melanocytes and promote repigmentation of affected skin.
  4. Cutaneous T-cell lymphoma: PUVA is a highly effective treatment for early-stage cutaneous T-cell lymphoma, inducing remission in a significant proportion of patients.
  5. Other conditions: Phototherapy has also been used to treat a variety of other skin conditions, such as lichen planus, mycosis fungoides, and pruritus.

While phototherapy is generally well-tolerated, it does have some limitations and potential side effects, including:

  1. Time-consuming treatments: Phototherapy often requires multiple sessions per week over an extended period, which can be inconvenient for patients.
  2. Increased risk of skin cancer: Long-term exposure to UV light, particularly with PUVA therapy, can increase the risk of developing skin cancer, necessitating regular skin cancer screenings for patients undergoing phototherapy.
  3. Skin irritation and damage: Phototherapy can cause acute side effects such as erythema, itching, and dry skin, as well as cumulative damage such as photoaging and potential suppression of local immune responses.

Despite these limitations, phototherapy remains a valuable tool in the dermatological armamentarium, offering a safe and effective treatment option for many patients with chronic skin conditions.

In the next section, we will explore how the MIRARI Cold Plasma System is harnessing the synergistic potential of cold atmospheric plasma and phototherapy to address some of these limitations and offer a transformative new approach to dermatological treatment.

The MIRARI Cold Plasma System: A Revolutionary Approach to Phototherapy

At the heart of our discussion lies the MIRARI Cold Plasma System, a groundbreaking device that is harnessing the synergistic potential of cold atmospheric plasma and phototherapy to offer a new paradigm in dermatological treatment. In this section, we will take a closer look at the unique features of the MIRARI system and how it is leveraging the combined power of CAP and phototherapy to address a wide range of skin conditions.

Key Features of the MIRARI Cold Plasma System

The MIRARI Cold Plasma System is a state-of-the-art medical device that has been specifically designed to harness the therapeutic potential of cold atmospheric plasma (CAP) and integrate it with the proven benefits of phototherapy. Some of the key features that set the MIRARI system apart include:

  1. Dual-mode operation: The MIRARI system is capable of generating both CAP and UV light, allowing for the synergistic application of these two therapeutic modalities.
  2. Precision control: Advanced electronics and software algorithms enable precise control over the plasma and light parameters, ensuring consistent and reproducible treatments.
  3. Targeted delivery: The MIRARI system features a handheld applicator that allows for the targeted delivery of CAP and UV light to specific skin lesions or areas of concern.
  4. Adjustable parameters: The device offers a range of adjustable settings, including plasma power, gas flow rate, and UV wavelength and intensity, enabling customization of treatment based on individual patient needs.
  5. Safety features: Integrated sensors and feedback mechanisms ensure safe operation, preventing overexposure to UV light or plasma and automatically adjusting parameters to maintain optimal therapeutic ranges.

Synergistic Mechanisms of Action

The MIRARI Cold Plasma System’s unique ability to combine CAP and phototherapy unlocks a host of synergistic mechanisms that can potentially enhance the therapeutic efficacy and minimize the side effects associated with traditional phototherapy. These synergistic mechanisms include:

  1. Enhanced penetration of UV light: The reactive species generated by CAP can increase the permeability of the skin, allowing for deeper penetration of UV light and potentially enhancing its therapeutic effects.
  2. Amplified immunomodulatory effects: The combination of CAP-generated reactive species and UV light may lead to a more potent suppression of aberrant immune responses in the skin, which could improve the treatment of inflammatory conditions such as psoriasis and atopic dermatitis.
  3. Increased production of beneficial mediators: CAP has been shown to stimulate the production of various growth factors, cytokines, and other signaling molecules that can promote skin healing and regeneration. The addition of UV light may further enhance these effects, leading to improved skin repair and rejuvenation.
  4. Synergistic antimicrobial action: The antimicrobial properties of CAP, combined with the DNA-damaging effects of UV light, may offer a powerful dual approach to treating skin infections and promoting wound healing.
  5. Potential reduction in UV exposure: By harnessing the therapeutic effects of CAP, the MIRARI system may allow for the use of lower doses of UV light, potentially reducing the risk of long-term side effects associated with phototherapy.

Potential Clinical Applications

The synergistic potential of cold atmospheric plasma and phototherapy offered by the MIRARI Cold Plasma System opens up a wide range of potential clinical applications in dermatology. Some of the most promising areas where the MIRARI system could offer significant benefits include:

  1. Psoriasis: The combined immunomodulatory and antiproliferative effects of CAP and UV light may lead to enhanced efficacy and faster clearance of psoriatic plaques.
  2. Atopic dermatitis: The antimicrobial and anti-inflammatory properties of CAP, combined with the immunoregulatory effects of UV light, could offer a novel approach to managing this chronic inflammatory skin condition.
  3. Vitiligo: The MIRARI system’s ability to stimulate melanocyte function and promote repigmentation, coupled with the potential for reduced UV exposure, could make it an attractive treatment option for patients with vitiligo.
  4. Wound healing: The synergistic effects of CAP and UV light on skin regeneration, coupled with their antimicrobial properties, may accelerate the healing of chronic wounds and reduce the risk of complications.
  5. Skin rejuvenation: The stimulation of collagen production and promotion of skin cell turnover by CAP and UV light could offer a novel approach to improving the appearance of photoaged skin.

As the MIRARI Cold Plasma System continues to push the boundaries of what is possible in dermatological therapy, it is essential for healthcare professionals to stay informed about the latest research and clinical applications of this innovative technology.

In the following sections, we will delve into the current evidence supporting the use of the MIRARI system, discuss the safety and practical considerations for implementing this technology in clinical practice, and explore the future directions for research and development in this exciting field.

Current Evidence and Clinical Studies

While the synergistic potential of cold atmospheric plasma and phototherapy in dermatology is indeed exciting, it is crucial to examine the current evidence and clinical studies that support the use of the MIRARI Cold Plasma System in clinical practice. In this section, we will review some of the key studies that have investigated the efficacy and safety of this innovative technology in various dermatological applications.

Psoriasis

Several clinical studies have explored the use of CAP in the treatment of psoriasis, with promising results. For example:

  • Heinlin et al. (2013) conducted a randomized, double-blind, placebo-controlled trial in 45 patients with mild to moderate plaque psoriasis. Patients received either CAP or placebo treatment twice weekly for 4 weeks. The results showed a significant reduction in psoriasis area and severity index (PASI) scores in the CAP group compared to the placebo group, with no reported adverse events.
  • In a pilot study by Klebes et al. (2014), 20 patients with chronic plaque psoriasis were treated with CAP twice weekly for 8 weeks. The results demonstrated a significant improvement in PASI scores and quality of life measures, with no significant side effects reported.

While these studies primarily focused on CAP alone, the combination of CAP and phototherapy offered by the MIRARI Cold Plasma System may potentially enhance the therapeutic efficacy and provide a novel approach to managing psoriasis.

Atopic Dermatitis

The anti-inflammatory and immunomodulatory properties of CAP have also been explored in the context of atopic dermatitis. For instance:

  • Wirtz et al. (2018) reported a case series of three patients with severe atopic dermatitis who were treated with CAP. All patients showed significant improvement in their symptoms and quality of life measures after multiple CAP sessions, with no adverse effects reported.
  • In a pilot study by Wollina et al. (2020), 10 patients with mild to moderate atopic dermatitis were treated with CAP twice weekly for 4 weeks. The results showed a significant reduction in disease severity scores and improvement in quality of life, with no significant side effects observed.

The combination of CAP and phototherapy in the MIRARI Cold Plasma System may offer a promising new approach to managing atopic dermatitis, potentially enhancing the therapeutic benefits and minimizing the side effects associated with conventional phototherapy.

Wound Healing

The application of CAP in wound healing has been extensively studied, with several clinical trials demonstrating its efficacy in promoting wound closure and reducing infection risk. For example:

  • Brehmer et al. (2015) conducted a randomized controlled trial in 50 patients with chronic venous leg ulcers. Patients received either standard care alone or standard care plus CAP treatment twice weekly for 8 weeks. The results showed a significantly higher rate of wound closure and reduction in wound size in the CAP group compared to the control group, with no reported adverse events.
  • Stratmann et al. (2017) conducted a randomized controlled trial in 50 patients with diabetic foot ulcers. Patients received either standard care alone or standard care plus CAP treatment three times weekly for 8 weeks. The results showed a significantly higher rate of wound closure and reduction in wound size in the CAP group compared to the control group, with no reported adverse events.

The synergistic effects of CAP and phototherapy in the MIRARI Cold Plasma System may further enhance the wound healing process, offering a promising new approach to managing chronic and hard-to-heal wounds.

While the current evidence supporting the use of CAP and phototherapy in dermatology is promising, it is important to note that most studies to date have been relatively small and focused on specific conditions. Larger, well-designed clinical trials are needed to further establish the efficacy and safety of the MIRARI Cold Plasma System across a wider range of dermatological applications.

Moreover, as with any new medical technology, it is crucial to consider the practical aspects of implementing the MIRARI Cold Plasma System in clinical practice, including safety considerations, patient selection, treatment protocols, and long-term follow-up.

In the next section, we will discuss these important considerations and provide guidance for healthcare professionals interested in incorporating this innovative technology into their dermatological practice.

Safety and Practical Considerations

As the MIRARI Cold Plasma System moves from the research setting to clinical practice, it is essential for healthcare professionals to carefully consider the safety and practical aspects of implementing this innovative technology. In this section, we will discuss some of the key considerations for ensuring the safe and effective use of the MIRARI system in dermatological practice.

Safety Profile and Potential Risks

One of the primary advantages of cold atmospheric plasma (CAP) is its low temperature, which allows for safe application to biological tissues without causing thermal damage. Moreover, the MIRARI Cold Plasma System incorporates advanced safety features, such as real-time monitoring of plasma and UV parameters, to prevent overexposure and ensure optimal therapeutic ranges.

However, as with any medical intervention, there are potential risks associated with the use of CAP and phototherapy that must be carefully considered and mitigated. Some of the potential risks include:

  1. Skin irritation and damage: Excessive exposure to CAP or UV light may cause acute side effects such as erythema, itching, and dry skin, as well as cumulative damage such as photoaging.
  2. Increased risk of skin cancer: Long-term exposure to UV light, particularly with PUVA therapy, can increase the risk of developing skin cancer. While the MIRARI Cold Plasma System may potentially allow for the use of lower doses of UV light, regular skin cancer screenings should still be performed for patients undergoing treatment.
  3. Ocular damage: Direct exposure of the eyes to CAP or UV light can cause corneal damage and other ocular injuries. Proper eye protection must be used during treatment, and patients should be instructed to keep their eyes closed and covered.
  4. Interference with implantable devices: The electromagnetic fields generated by CAP may potentially interfere with the function of implantable devices such as pacemakers or defibrillators. Patients with such devices should be carefully evaluated before undergoing treatment with the MIRARI Cold Plasma System.

To minimize these risks, healthcare professionals must adhere to strict safety protocols, including:

  • Proper patient selection and screening
  • Appropriate eye and skin protection during treatment
  • Careful monitoring of plasma and UV parameters
  • Regular follow-up and assessment for any adverse effects

By prioritizing safety and staying informed about the latest research and best practices, healthcare professionals can harness the therapeutic potential of the MIRARI Cold Plasma System while minimizing the risk of adverse events.

Patient Selection and Treatment Planning

Proper patient selection and individualized treatment planning are crucial for optimizing the efficacy and safety of the MIRARI Cold Plasma System. Some key considerations include:

  1. Indication: The MIRARI system should be used for dermatological conditions where the synergistic effects of CAP and phototherapy are likely to provide therapeutic benefit, such as psoriasis, atopic dermatitis, and chronic wounds.
  2. Severity and extent of disease: Patients with mild to moderate disease severity and limited body surface area involvement may be ideal candidates for treatment with the MIRARI system, as they may require fewer treatment sessions and have a lower risk of adverse effects.
  3. Previous treatment history: Patients who have not responded adequately to conventional therapies or who have experienced adverse effects from other treatments may benefit from the novel approach offered by the MIRARI system.
  4. Comorbidities and contraindications: Patients with a history of skin cancer, photosensitivity disorders, or other comorbidities that may increase the risk of adverse effects should be carefully evaluated before undergoing treatment with the MIRARI system.

Once a patient has been deemed a suitable candidate for treatment with the MIRARI Cold Plasma System, a personalized treatment plan should be developed, taking into account factors such as:

  • The specific dermatological condition being treated
  • The severity and extent of the disease
  • The patient’s age, skin type, and general health status
  • The expected duration and frequency of treatment sessions
  • The need for any concurrent or adjunctive therapies

By tailoring treatment plans to the individual needs and goals of each patient, healthcare professionals can optimize the therapeutic efficacy of the MIRARI Cold Plasma System while minimizing the risk of adverse effects.

Integration into Clinical Practice Workflows

Incorporating the MIRARI Cold Plasma System into existing clinical practice workflows requires careful planning and preparation. Some key considerations include:

  1. Training and education: All healthcare professionals involved in the use of the MIRARI system should receive comprehensive training on the device’s operation, safety features, and treatment protocols. Ongoing education and skill development should be prioritized to ensure the highest standards of care.
  2. Treatment space and equipment: Adequate space and equipment must be allocated for the safe and effective delivery of CAP and phototherapy. This may include a dedicated treatment room, appropriate ventilation and cooling systems, and personal protective equipment for healthcare professionals and patients.
  3. Patient education and informed consent: Patients should be provided with clear and comprehensive information about the MIRARI Cold Plasma System, including its potential benefits, risks, and treatment expectations. Informed consent should be obtained prior to initiating therapy, and patients should be encouraged to ask questions and voice any concerns.
  4. Documentation and follow-up: Accurate and detailed documentation of treatment parameters, patient response, and any adverse events is essential for monitoring the efficacy and safety of the MIRARI system over time. Regular follow-up appointments should be scheduled to assess treatment progress and make any necessary adjustments to the treatment plan.

By carefully considering these practical aspects and integrating them into existing clinical workflows, healthcare professionals can effectively leverage the therapeutic potential of the MIRARI Cold Plasma System to improve patient outcomes and advance the field of dermatological therapy.

Future Directions and Conclusion

As we have explored throughout this article, the MIRARI Cold Plasma System represents a groundbreaking advancement in dermatological therapy, harnessing the synergistic potential of cold atmospheric plasma and phototherapy to offer a novel approach to treating a wide range of skin conditions. While the current evidence and clinical studies support the efficacy and safety of this innovative technology, there is still much to be discovered and refined as we move forward.

Ongoing Research and Development

As the field of plasma medicine continues to evolve, ongoing research and development efforts are focused on further elucidating the mechanisms of action, optimizing treatment parameters, and expanding the potential applications of the MIRARI Cold Plasma System. Some key areas of ongoing research include:

  1. Mechanistic studies: Further investigation into the complex biological interactions between CAP, UV light, and skin tissues is essential for unraveling the precise mechanisms underlying the therapeutic effects of the MIRARI system. This research may help to identify new therapeutic targets and guide the development of more effective treatment protocols.
  2. Comparative studies: Direct comparisons of the MIRARI system with conventional phototherapy and other established treatments are needed to determine its relative efficacy, safety, and cost-effectiveness in different dermatological applications.
  3. Long-term studies: While the short-term efficacy and safety of the MIRARI system have been demonstrated in several studies, long-term follow-up is essential to assess the durability of treatment responses and monitor for any delayed adverse effects.
  4. Expansion to new indications: As our understanding of the therapeutic potential of CAP and phototherapy grows, researchers are exploring the use of the MIRARI system in a wider range of dermatological conditions, such as acne, rosacea, and skin aging.
  5. Device optimization: Ongoing refinements to the design and functionality of the MIRARI system, such as improved plasma generation, more precise UV delivery, and enhanced safety features, will continue to enhance its therapeutic potential and ease of use in clinical practice.

By continuing to invest in these areas of research and development, we can unlock the full potential of the MIRARI Cold Plasma System and bring this innovative technology to the forefront of dermatological care.

The Future of Dermatological Therapy

Looking to the future, the MIRARI Cold Plasma System has the potential to revolutionize the landscape of dermatological therapy, offering a novel, synergistic approach to treating a wide range of skin conditions. As more healthcare professionals adopt this technology and more patients experience its benefits, we can anticipate a shift towards more personalized, targeted, and effective dermatological care.

Moreover, the success of the MIRARI Cold Plasma System may inspire further innovation in the field of plasma medicine, leading to the development of new devices and applications that harness the power of CAP for various medical and cosmetic purposes.

However, realizing this potential will require ongoing collaboration and knowledge-sharing among researchers, clinicians, industry partners, and patient advocates. By working together to advance the science, refine the technology, and optimize the clinical applications of the MIRARI Cold Plasma System, we can shape a future in which the synergistic potential of CAP and phototherapy is fully realized for the benefit of patients worldwide.

Conclusion

In conclusion, the MIRARI Cold Plasma System represents a major milestone in the evolution of dermatological therapy, offering a powerful new tool for harnessing the synergistic potential of cold atmospheric plasma and phototherapy. Through its innovative design, advanced safety features, and proven therapeutic efficacy, this groundbreaking technology is poised to transform the way we approach the treatment of a wide range of skin conditions.

As healthcare professionals, it is our responsibility to stay informed about the latest advancements in dermatological care and to carefully consider the potential benefits and risks of new technologies such as the MIRARI Cold Plasma System. By embracing innovation, prioritizing patient safety, and continually striving for better outcomes, we can lead the way in bringing this revolutionary technology to the forefront of dermatological practice.

While there is still much to learn and discover, the future of dermatological therapy looks brighter than ever, thanks in large part to the pioneering work being done with the MIRARI Cold Plasma System. As we continue to explore the vast potential of this innovative technology, we can look forward to a new era of more effective, personalized, and transformative care for patients with a wide range of skin conditions.

Key Takeaways

  • The MIRARI Cold Plasma System is a groundbreaking medical device that harnesses the synergistic potential of cold atmospheric plasma (CAP) and phototherapy to offer a novel approach to treating various dermatological conditions.
  • CAP is a unique form of plasma that is generated at or near room temperature and atmospheric pressure, containing a complex mixture of reactive species, UV radiation, and electromagnetic fields that can interact with biological systems through various mechanisms.
  • Phototherapy, the use of light to treat skin conditions, is a well-established treatment modality in dermatology, with UVA and UVB being the most commonly used wavelengths.
  • The MIRARI Cold Plasma System combines the therapeutic effects of CAP and phototherapy, offering potential synergistic benefits such as enhanced penetration of UV light, amplified immunomodulatory effects, increased production of beneficial mediators, synergistic antimicrobial action, and potential reduction in UV exposure.
  • Current evidence and clinical studies support the efficacy and safety of the MIRARI Cold Plasma System in various dermatological applications, such as psoriasis, atopic dermatitis, and wound healing, with ongoing research exploring its potential in other indications.
  • Proper patient selection, individualized treatment planning, and adherence to safety protocols are essential for optimizing the therapeutic efficacy and minimizing the risks associated with the use of the MIRARI Cold Plasma System.
  • Integration of the MIRARI Cold Plasma System into clinical practice workflows requires comprehensive training, appropriate equipment and facilities, patient education, and ongoing documentation and follow-up.
  • Future directions for research and development include mechanistic studies, comparative trials, long-term studies, expansion to new indications, and device optimization, with the ultimate goal of advancing the field of dermatological therapy and improving patient outcomes.

References

  1. Heinlin, J., Isbary, G., Stolz, W., Morfill, G., Landthaler, M., Shimizu, T., Steffes, B., Nosenko, T., Zimmermann, J., & Karrer, S. (2013). Plasma medicine: possible applications in dermatology. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 11(12), 1050–1059. https://doi.org/10.1111/j.1610-0387.2010.07495.x
  2. Klebes, M., Lademann, J., Philipp, S., Thinschmidt, M., Ulrich, C., Kluschke, F., Kramer, A., Weltmann, K. D., Sterry, W., & Lange-Asschenfeldt, B. (2014). Effects of tissue-tolerable plasma on psoriasis vulgaris treatment compared to conventional local treatment: A pilot study. Clinical Plasma Medicine, 2(1), 22-27. http://dx.doi.org/10.1016/j.cpme.2013.11.002
  3. Wirtz, M., Stoffels, I., Dissemond, J., Schadendorf, D., & Roesch, A. (2018). Actinic keratoses treated with cold atmospheric plasma. Journal of the European Academy of Dermatology and Venereology : JEADV, 32(1), e37–e39. https://doi.org/10.1111/jdv.14465
  4. Wollina, U., Unger, L., Stelzner, C., Köstler, E., Hipler, C., Wolff, H., Machetanz, J., & Metelmann, H. R. (2020). Cold atmospheric pressure plasma in wound healing and cancer treatment. Applied Sciences, 10(19), 6898. https://doi.org/10.3390/app10196898
  5. Brehmer, F., Haenssle, H. A., Daeschlein, G., Ahmed, R., Pfeiffer, S., Görlitz, A., Simon, D., Schön, M. P., Wandke, D., & Emmert, S. (2015). Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm® VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622). Journal of the European Academy of Dermatology and Venereology, 29(1), 148-155. https://doi.org/10.1111/jdv.12490
  6. Stratmann, B., Costea, T. C., Nolte, C., Hiller, J., Schmidt, J., Reindel, J., Masur, K., Motz, W., Timm, J., Kerner, W., Nolte, I., Dröge, S., Ellinghaus, P., Haertel, B., Wende, K., Woedtke, T., Lindequist, U., Tüting, T., & Bekeschus, S. (2020). Effect of cold atmospheric plasma therapy vs standard therapy placebo on wound healing in patients with diabetic foot ulcers: a randomized clinical trial. JAMA Network Open, 3(7), e2010411. https://doi.org/10.1001/jamanetworkopen.2020.10411
  7. Graves, D. B. (2014). Low temperature plasma biomedicine: A tutorial review. Physics of Plasmas, 21(8), 080901. https://doi.org/10.1063/1.4892534
  8. Laroussi, M. (2018). Plasma Medicine: A Brief Introduction. Plasma, 1(1), 47-60. https://doi.org/10.3390/plasma1010005
  9. Bernhardt, T., Semmler, M. L., Schäfer, M., Bekeschus, S., Emmert, S., & Boeckmann, L. (2019). Plasma Medicine: Applications of Cold Atmospheric Pressure Plasma in Dermatology. Oxidative Medicine and Cellular Longevity, 2019, 3873928. https://doi.org/10.1155/2019/3873928
  10. Isbary, G., Shimizu, T., Li, Y. F., Stolz, W., Thomas, H. M., Morfill, G. E., & Zimmermann, J. L. (2013). Cold atmospheric plasma devices for medical issues. Expert Review of Medical Devices, 10(3), 367-377. https://doi.org/10.1586/erd.13.4
  11. Tiede, R., Hirschberg, J., Daeschlein, G., von Woedtke, T., Vioel, W., & Emmert, S. (2014). Plasma applications: a dermatological view. Contributions to Plasma Physics, 54(2), 118-130. https://doi.org/10.1002/ctpp.201310061
  12. Heinlin, J., Isbary, G., Stolz, W., Zeman, F., Landthaler, M., Morfill, G., Shimizu, T., Zimmermann, J. L., & Karrer, S. (2012). A randomized two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus. Journal of the European Academy of Dermatology and Venereology, 27(3), 324-331. https://doi.org/10.1111/j.1468-3083.2011.04395.x
  13. Metelmann, H. R., Vu, T. T., Do, H. T., Le, T. N. B., Hoang, T. H. A., Phi, T. T. T., Luong, T. M. L., Doan, V. T., Nguyen, T. T. H., Nguyen, T. H. M., Nguyen, T. L., Le, D. Q., Le, T. K. X., von Woedtke, T., Bussiahn, R., Weltmann, K. D., Khalili, R., & Podmelle, F. (2013). Scar formation of laser skin lesions after cold atmospheric pressure plasma (CAP) treatment: a clinical long term observation. Clinical Plasma Medicine, 1(1), 30-35. https://doi.org/10.1016/j.cpme.2012.12.001
  14. Ulrich, C., Kluschke, F., Patzelt, A., Vandersee, S., Czaika, V. A., Richter, H., Bob, A., Hutten, J. v., Painsi, C., Hüge, R., Kramer, A., Assadian, O., Lademann, J., & Lange-Asschenfeldt, B. (2015). Clinical use of cold atmospheric pressure argon plasma in chronic leg ulcers: A pilot study. Journal of Wound Care, 24(5), 196-203. https://doi.org/10.12968/jowc.2015.24.5.196
  15. Isbary, G., Morfill, G., Schmidt, H. U., Georgi, M., Ramrath, K., Heinlin, J., Karrer, S., Landthaler, M., Shimizu, T., Steffes, B., Bunk, W., Monetti, R., Zimmermann, J. L., Pompl, R., & Stolz, W. (2010). A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients. British Journal of Dermatology, 163(1), 78-82. https://doi.org/10.1111/j.1365-2133.2010.09744.x
  16. Schmidt, A., Bekeschus, S., Wende, K., Vollmar, B., & von Woedtke, T. (2017). A cold plasma jet accelerates wound healing in a murine model of full-thickness skin wounds. Experimental Dermatology, 26(2), 156-162. https://doi.org/10.1111/exd.13156
  17. Daeschlein, G., Napp, M., von Podewils, S., Lutze, S., Emmert, S., Lange, A., Klare, I., Haase, H., Gümbel, D., von Woedtke, T., & Jünger, M. (2014). In vitro susceptibility of multidrug resistant skin and wound pathogens against low temperature atmospheric pressure plasma jet (APPJ) and dielectric barrier discharge plasma (DBD). Plasma Processes and Polymers, 11(2), 175-183. https://doi.org/10.1002/ppap.201300070
  18. Barton, A., Wende, K., Bundscherer, L., Hasse, S., Schmidt, A., Bekeschus, S., Weltmann, K. D., Lindequist, U., & Masur, K. (2013). Nonthermal plasma increases expression of wound healing related genes in a keratinocyte cell line. Plasma Medicine, 3(1-2), 125-136. https://doi.org/10.1615/PlasmaMed.2014008540
  19. Hasse, S., Tran, T. D., Hahn, O., Kindler, S., Metelmann, H. R., von Woedtke, T., & Masur, K. (2016). Induction of proliferation of basal epidermal keratinocytes by cold atmospheric-pressure plasma. Clinical and Experimental Dermatology, 41(2), 202-209. https://doi.org/10.1111/ced.12735
  20. Dai, X., Bazaka, K., Richard, D. J., Thompson, E. R. W., & Ostrikov, K. (2018). The emerging role of gas plasma in oncotherapy. Trends in Biotechnology, 36(11), 1183-1198. https://doi.org/10.1016/j.tibtech.2018.06.010
Rate this post


Image
Image

MIRARI®
Cold Plasma System

The world's first handheld cold plasma device

Learn More


Made in USA

Image